Download PDF
Semin Liver Dis 2016; 36(04): 354-359
DOI: 10.1055/s-0036-1594009
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

The Microbiome: What Will the Future Hold?

Howard Paul Monsour Jr.
1   Section of Hepatology, Department of Medicine, Houston Methodist Hospital, Weill Cornell Medical College, Houston, Texas
,
Eamonn M. M. Quigley
2   Lynda K and David M Underwood Center for Digestive Disorders, Houston Methodist Hospital, Weill Cornell Medical College, Houston, Texas
› Author Affiliations
Further Information

Publication History

Publication Date:
20 December 2016 (online)

    Permissions and Reprints

Abstract

Current research on the human microbiome has opened our eyes to the intimate relationship that we have with the bacteria that populate our gastrointestinal tract and its potential relationship to health and disease. To date, clinical research on the microbiome has identified intriguing associations between an altered microbiome and disease states, but proven therapeutic applications have been very limited. The ingestion of prebiotics, probiotics, and/or synbiotics is appealing to the general public and has significant commercial value, but as yet, solid evidence for clinical efficacy in liver disease has been lacking due, in large part, to the paucity of high-quality clinical trials. On the other hand, the resounding success of fecal microbiota transplantation in Clostridium difficile infection has opened our eyes to the real potential of “pharmabiotics” and may well provide an intriguing template for the development of novel approaches to modulate the microbiome and its interactions with the host and thereby treat and/or prevent disease states. We will attempt to examine the current state of microbiome therapeutics and predict how these approaches might fit into the management of liver diseases in the future.

Keywords

microbiome - pharmabiotics - diet - fecal microbiota transplantation
 

  • References

  • 1 Pray L, Pillsbury L, Tomayko E. The Human Microbiome, Diet, and Health—Workshop Summary. Washington, DC: National Academies Press; 2013
    Google Scholar
  • 2 Martin R, Makino H, Cetinyurek Yavuz A , et al. Early-life events, including mode of delivery and type of feeding, siblings and gender, shape the developing gut microbiota. PLoS One 2016; 11 (6) e0158498
    CrossrefPubMedGoogle Scholar
  • 3 Sonnenburg ED, Smits SA, Tikhonov M, Higginbottom SK, Wingreen NS, Sonnenburg JL. Diet-induced extinctions in the gut microbiota compound over generations. Nature 2016; 529 (7585) 212-215
    CrossrefPubMedGoogle Scholar
  • 4 Jiménez E, Marín ML, Martín R , et al. Is meconium from healthy newborns actually sterile?. Res Microbiol 2008; 159 (3) 187-193
    CrossrefPubMedGoogle Scholar
  • 5 Scharschmidt TC, Fischbach MA. What lives on our skin: ecology, genomics and therapeutic opportunities of the skin microbiome. Drug Discov Today Dis Mech 2013; 10 (3–4) e83-e89
    PubMedGoogle Scholar
  • 6 Koenig JE, Spor A, Scalfone N , et al. Succession of microbial consortia in the developing infant gut microbiome. Proc Natl Acad Sci U S A 2011; 108 (Suppl. 01) 4578-4585
    CrossrefPubMedGoogle Scholar
  • 7 Maynard CL, Elson CO, Hatton RD, Weaver CT. Reciprocal interactions of the intestinal microbiota and immune system. Nature 2012; 489 (7415) 231-241
    CrossrefPubMedGoogle Scholar
  • 8 Matamoros S, Gras-Leguen C, Le Vacon F, Potel G, de La Cochetiere MF. Development of intestinal microbiota in infants and its impact on health. Trends Microbiol 2013; 21 (4) 167-173
    CrossrefPubMedGoogle Scholar
  • 9 Praveen P, Jordan F, Priami C, Morine MJ. The role of breast-feeding in infant immune system: a systems perspective on the intestinal microbiome. Microbiome 2015; 3: 41
    CrossrefPubMedGoogle Scholar
  • 10 Ley RE, Bäckhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A 2005; 102 (31) 11070-11075
    CrossrefPubMedGoogle Scholar
  • 11 Hollister EB, Riehle K, Luna RA , et al. Structure and function of the healthy pre-adolescent pediatric gut microbiome. Microbiome 2015; 3: 36
    CrossrefPubMedGoogle Scholar
  • 12 Heiman ML, Greenway FL. A healthy gastrointestinal microbiome is dependent on dietary diversity. Mol Metab 2016; 5 (5) 317-320
    PubMedGoogle Scholar
  • 13 Food and Agricultural Organization of the United Nations (FAO). Agrobiodiversity?. Rome, Italy: FAO; 2004
    PubMedGoogle Scholar
  • 14 Koch H, Schauder P, Schäfer G , et al. [Diagnosis and prevalence of latent hepatic encephalopathy]. Z Gastroenterol 1990; 28 (11) 610-615
    PubMedGoogle Scholar
  • 15 Patidar KR, Thacker LR, Wade JB , et al. Covert hepatic encephalopathy is independently associated with poor survival and increased risk of hospitalization. Am J Gastroenterol 2014; 109 (11) 1757-1763
    CrossrefPubMedGoogle Scholar
  • 16 Jepsen P, Ott P, Andersen PK, Sørensen HT, Vilstrup H. Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study. Hepatology 2010; 51 (5) 1675-1682
    CrossrefPubMedGoogle Scholar
  • 17 Kimer N, Krag A, Møller S, Bendtsen F, Gluud LL. Systematic review with meta-analysis: the effects of rifaximin in hepatic encephalopathy. Aliment Pharmacol Ther 2014; 40 (2) 123-132
    CrossrefPubMedGoogle Scholar
  • 18 Vlachogiannakos J, Viazis N, Vasianopoulou P, Vafiadis I, Karamanolis DG, Ladas SD. Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis. J Gastroenterol Hepatol 2013; 28 (3) 450-455
    CrossrefPubMedGoogle Scholar
  • 19 Bajaj JS, Hylemon PB, Ridlon JM , et al. Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. Am J Physiol Gastrointest Liver Physiol 2012; 303 (6) G675-G685
    CrossrefPubMedGoogle Scholar
  • 20 Kalambokis GN, Mouzaki A, Rodi M , et al. Rifaximin improves systemic hemodynamics and renal function in patients with alcohol-related cirrhosis and ascites. Clin Gastroenterol Hepatol 2012; 10 (7) 815-818
    CrossrefPubMedGoogle Scholar
  • 21 Bajaj JS. Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis. Aliment Pharmacol Ther 2016; 43 (Suppl. 01) 11-26
    CrossrefPubMedGoogle Scholar
  • 22 Sharma BC, Singh J. Probiotics in management of hepatic encephalopathy. Metab Brain Dis 2016; 31 (6) 1295-1301
    CrossrefPubMedGoogle Scholar
  • 23 Shukla S, Shukla A, Mehboob S, Guha S. Meta-analysis: the effects of gut flora modulation using prebiotics, probiotics and synbiotics on minimal hepatic encephalopathy. Aliment Pharmacol Ther 2011; 33 (6) 662-671
    CrossrefPubMedGoogle Scholar
  • 24 Holte K, Krag A, Gluud LL. Systematic review and meta-analysis of randomized trials on probiotics for hepatic encephalopathy. Hepatol Res 2012; 42 (10) 1008-1015
    CrossrefPubMedGoogle Scholar
  • 25 Saab S, Suraweera D, Au J, Saab EG, Alper TS, Tong MJ. Probiotics are helpful in hepatic encephalopathy: a meta-analysis of randomized trials. Liver Int 2016; 36 (7) 986-993
    CrossrefPubMedGoogle Scholar
  • 26 Xu J, Ma R, Chen LF, Zhao LJ, Chen K, Zhang RB. Effects of probiotic therapy on hepatic encephalopathy in patients with liver cirrhosis: an updated meta-analysis of six randomized controlled trials. Hepatobiliary Pancreat Dis Int 2014; 13 (4) 354-360
    CrossrefPubMedGoogle Scholar
  • 27 Shen TC, Albenberg L, Bittinger K , et al. Engineering the gut microbiota to treat hyperammonemia. J Clin Invest 2015; 125 (7) 2841-2850
    CrossrefPubMedGoogle Scholar
  • 28 Shen TC, Chehoud C, Ni J , et al. Dietary regulation of the gut microbiota engineered by a minimal defined bacterial consortium. PLoS One 2016; 11 (5) e0155620
    CrossrefPubMedGoogle Scholar
  • 29 Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 2013; 10 (11) 686-690
    CrossrefPubMedGoogle Scholar
  • 30 Oben JA, Mouralidarane A, Samuelsson AM , et al. Maternal obesity during pregnancy and lactation programs the development of offspring non-alcoholic fatty liver disease in mice. J Hepatol 2010; 52 (6) 913-920
    PubMedGoogle Scholar
  • 31 Leung C, Rivera L, Furness JB, Angus PW. The role of the gut microbiota in NAFLD. Nat Rev Gastroenterol Hepatol 2016; 13 (7) 412-425
    CrossrefPubMedGoogle Scholar
  • 32 Vrieze A, Van Nood E, Holleman F , et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012; 143 (4) 913-6.e7
    CrossrefPubMedGoogle Scholar
  • 33 Paolella G, Mandato C, Pierri L, Poeta M, Di Stasi M, Vajro P. Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20 (42) 15518-15531
    Google Scholar
  • 34 Ma YY, Li L, Yu CH, Shen Z, Chen LH, Li YM. Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis. World J Gastroenterol 2013; 19 (40) 6911-6918
    CrossrefPubMedGoogle Scholar
  • 35 Shimizu M, Hashiguchi M, Shiga T, Tamura HO, Mochizuki M. Meta-analysis: effects of probiotic supplementation on lipid profiles in normal to mildly hypercholesterolemic individuals. PLoS One 2015; 10 (10) e0139795
    CrossrefPubMedGoogle Scholar
  • 36 Ferolla SM, Armiliato GN, Couto CA, Ferrari TC. Probiotics as a complementary therapeutic approach in nonalcoholic fatty liver disease. World J Hepatol 2015; 7 (3) 559-565
    CrossrefPubMedGoogle Scholar
  • 37 Lunia MK, Sharma BC, Sharma P, Sachdeva S, Srivastava S. Probiotics prevent hepatic encephalopathy in patients with cirrhosis: a randomized controlled trial. Clin Gastroenterol Hepatol 2014; 12 (6) 1003-8.e1
    CrossrefPubMedGoogle Scholar
  • 38 Dhiman RK, Rana B, Agrawal S , et al. Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial. Gastroenterology 2014; 147 (6) 1327-37.e3
    CrossrefPubMedGoogle Scholar
  • 39 Victor III DW, Quigley EM. Hepatic encephalopathy involves interactions among the microbiota, gut, brain. Clin Gastroenterol Hepatol 2014; 12 (6) 1009-1011
    CrossrefPubMedGoogle Scholar
  • 40 Victor III DW, Quigley EM. Microbial therapy in liver disease: probiotics probe the microbiome-gut-liver-brain axis. Gastroenterology 2014; 147 (6) 1216-1218
    CrossrefPubMedGoogle Scholar
  • 41 Zhang F, Luo W, Shi Y, Fan Z, Ji G. Should we standardize the 1,700-year-old fecal microbiota transplantation?. Am J Gastroenterol 2012; 107 (11) 1755 , author reply 1755–1756
    PubMedGoogle Scholar
  • 42 Eiseman B, Silen W, Bascom GS, Kauvar AJ. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 1958; 44 (5) 854-859
    PubMedGoogle Scholar
  • 43 Kassam Z, Lee CH, Yuan Y, Hunt RH. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol 2013; 108 (4) 500-508
    CrossrefPubMedGoogle Scholar
  • 44 Cammarota G, Ianiro G, Gasbarrini A. Fecal microbiota transplantation for the treatment of Clostridium difficile infection: a systematic review. J Clin Gastroenterol 2014; 48 (8) 693-702
    CrossrefPubMedGoogle Scholar
  • 45 Ofosu A. Clostridium difficile infection: a review of current and emerging therapies. Ann Gastroenterol 2016; 29 (2) 147-154
    PubMedGoogle Scholar
  • 46 Shi Y, Dong Y, Huang W, Zhu D, Mao H, Su P. Fecal microbiota transplantation for ulcerative colitis: a systematic review and meta-analysis. PLoS One 2016; 11 (6) e0157259
    CrossrefPubMedGoogle Scholar
  • 47 Ge X, Tian H, Ding C , et al. Fecal microbiota transplantation in combination with the soluble dietary fiber for the treatment of slow transit constipation: a pilot study. Arch Med Res 2016; 47 (3) 236-242
    CrossrefPubMedGoogle Scholar
  • 48 Kao D, Roach B, Park H , et al. Fecal microbiota transplantation in the management of hepatic encephalopathy. Hepatology 2016; 63 (1) 339-340
    CrossrefPubMedGoogle Scholar
  • 49 Manges AR, Steiner TS, Wright AJ. Fecal microbiota transplantation for the intestinal decolonization of extensively antimicrobial-resistant opportunistic pathogens: a review. Infect Dis (Lond) 2016; 48 (8) 587-592
    CrossrefPubMedGoogle Scholar
  • 50 Santoro-Lopes G, de Gouvêa EF. Multidrug-resistant bacterial infections after liver transplantation: an ever-growing challenge. World J Gastroenterol 2014; 20 (20) 6201-6210
    CrossrefPubMedGoogle Scholar
  • 51 Pinheiro HS, Mituiassu AM, Carminatti M, Braga AM, Bastos MG. Urinary tract infection caused by extended-spectrum beta-lactamase–producing bacteria in kidney transplant patients. Transplant Proc 2010; 42 (2) 486-487
    CrossrefPubMedGoogle Scholar
  • 52 Dubberke E, Mullane KM, Gerding DN , et al. Clearance of vancomycin-resistant Enterococcus concomitant with administration of a microbiota-based drug targeted at recurrent Clostridium difficile infection. Open Forum Infect Dis 2016; 3: ofw133
    CrossrefPubMedGoogle Scholar
  • 53 Khanna S, Pardi DS, Kelly CR , et al. A novel microbiome therapeutic increases gut microbial diversity and prevents recurrent Clostridium difficile infection. J Infect Dis 2016; 214: 173-181
    CrossrefPubMedGoogle Scholar
  • 54 Lagier JC, Million M, Fournier PE, Brouqui P, Raoult D. Faecal microbiota transplantation for stool decolonization of OXA-48 carbapenemase-producing Klebsiella pneumoniae . J Hosp Infect 2015; 90 (2) 173-174
    CrossrefPubMedGoogle Scholar
  • 55 Choi HH, Cho YS. Fecal microbiota transplantation: current applications, effectiveness, and future perspectives. Clin Endosc 2016; 49 (3) 257-265
    CrossrefPubMedGoogle Scholar
  • 56 Gupta S, Allen-Vercoe E, Petrof EO. Fecal microbiota transplantation: in perspective. Therap Adv Gastroenterol 2016; 9 (2) 229-239
    CrossrefPubMedGoogle Scholar
  • 57 Paramsothy S, Walsh AJ, Borody T , et al. Gastroenterologist perceptions of faecal microbiota transplantation. World J Gastroenterol 2015; 21 (38) 10907-10914
    CrossrefPubMedGoogle Scholar
  • 58 Kahn SA, Vachon A, Rodriquez D , et al. Patient perceptions of fecal microbiota transplantation for ulcerative colitis. Inflamm Bowel Dis 2013; 19 (7) 1506-1513
    CrossrefPubMedGoogle Scholar